Apixaban plasma concentrations before and after catheter ablation for atrial fibrillation.
Rachel AakerøyJan Pål LoennechenRoar DyrkornStian LydersenArne HellandOlav SpigsetPublished in: PloS one (2024)
In patients undergoing catheter ablation for atrial fibrillation, age, sex, renal function, interacting drugs and cerebrovascular risk profile were all associated with altered plasma apixaban concentration. In this group of patients with a generally high self-reported adherence, intra-individual variability was modest, but the inter-individual variability was substantial, and similar to those previously reported in other patient apixaban-treated populations. If a therapeutic concentration range is established, there might be a need for a more flexible approach to apixaban dosing, guided by therapeutic drug monitoring.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- left atrial appendage
- oral anticoagulants
- patients undergoing
- direct oral anticoagulants
- heart failure
- percutaneous coronary intervention
- venous thromboembolism
- case report
- type diabetes
- skeletal muscle
- coronary artery disease
- metabolic syndrome
- acute coronary syndrome
- protein kinase
- newly diagnosed
- solid state